119 related articles for article (PubMed ID: 9231056)
1. The c-erbB-2/neu proto-oncogene in human pituitary tumours.
Ezzat S; Zheng L; Smyth HS; Asa SL
Clin Endocrinol (Oxf); 1997 May; 46(5):599-606. PubMed ID: 9231056
[TBL] [Abstract][Full Text] [Related]
2. Cytoplasmic staining of erbB-2 but not mRNA levels correlates with differentiation in human thyroid neoplasia.
Sugg SL; Ezzat S; Zheng L; Rosen IB; Freeman JL; Asa SL
Clin Endocrinol (Oxf); 1998 Nov; 49(5):629-37. PubMed ID: 10197079
[TBL] [Abstract][Full Text] [Related]
3. Human TRH receptor messenger ribonucleic acid levels in normal and adenomatous pituitary: analysis by the competitive reverse transcription polymerase chain reaction method.
Kaji H; Xu Y; Takahashi Y; Abe H; Tamaki N; Chihara K
Clin Endocrinol (Oxf); 1995 Mar; 42(3):243-8. PubMed ID: 7758228
[TBL] [Abstract][Full Text] [Related]
4. Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor.
Kola B; Korbonits M; Diaz-Cano S; Kaltsas G; Morris DG; Jordan S; Metherell L; Powell M; Czirják S; Arnaldi G; Bustin S; Boscaro M; Mantero F; Grossman AB
Clin Endocrinol (Oxf); 2003 Sep; 59(3):328-38. PubMed ID: 12919156
[TBL] [Abstract][Full Text] [Related]
5. p53 gene mutations in pituitary adenomas: rare events.
Levy A; Hall L; Yeudall WA; Lightman SL
Clin Endocrinol (Oxf); 1994 Dec; 41(6):809-14. PubMed ID: 7889618
[TBL] [Abstract][Full Text] [Related]
6. Expression of Neuropeptide Y and Its Relationship with Molecular and Morphological Changes in Human Pituitary Adenomas.
Jia R; Li M; Chang B; Chen L; Ma J
Cancer Biother Radiopharm; 2015 Dec; 30(10):411-9. PubMed ID: 26683132
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of the Notch3 receptor in non-functioning pituitary tumours.
Miao Z; Miao Y; Lin Y; Lu X
J Clin Neurosci; 2012 Jan; 19(1):107-10. PubMed ID: 22153798
[TBL] [Abstract][Full Text] [Related]
8. Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours.
Vax VV; Bibi R; Diaz-Cano S; Gueorguiev M; Kola B; Borboli N; Bressac-de Paillerets B; Walker GJ; Dedov II; Grossman AB; Korbonits M
J Endocrinol; 2003 Aug; 178(2):301-10. PubMed ID: 12904177
[TBL] [Abstract][Full Text] [Related]
9. Galanin in human pituitary adenomas: frequency and clinical significance.
Leung B; Iisma TP; Leung KC; Hort YJ; Turner J; Sheehy JP; Ho KK
Clin Endocrinol (Oxf); 2002 Mar; 56(3):397-403. PubMed ID: 11940053
[TBL] [Abstract][Full Text] [Related]
10. Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour.
McCabe CJ; Khaira JS; Boelaert K; Heaney AP; Tannahill LA; Hussain S; Mitchell R; Olliff J; Sheppard MC; Franklyn JA; Gittoes NJ
Clin Endocrinol (Oxf); 2003 Feb; 58(2):141-50. PubMed ID: 12580928
[TBL] [Abstract][Full Text] [Related]
11. Oncoprotein immunoreactivity in human pituitary tumours.
Raghavan R; Harrison D; Ince PG; James RA; Daniels M; Birch P; Caldwell GI; Kendall-Taylor P
Clin Endocrinol (Oxf); 1994 Jan; 40(1):117-26. PubMed ID: 8306470
[TBL] [Abstract][Full Text] [Related]
12. Structure of the thyrotrophin-releasing hormone receptor in human pituitary adenomas.
Faccenda E; Melmed S; Bevan JS; Eidne KA
Clin Endocrinol (Oxf); 1996 Mar; 44(3):341-7. PubMed ID: 8729534
[TBL] [Abstract][Full Text] [Related]
13. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas.
Ewing I; Pedder-Smith S; Franchi G; Ruscica M; Emery M; Vax V; Garcia E; Czirják S; Hanzély Z; Kola B; Korbonits M; Grossman AB
Clin Endocrinol (Oxf); 2007 Mar; 66(3):348-52. PubMed ID: 17302867
[TBL] [Abstract][Full Text] [Related]
14. Oncogene profile of papillary thyroid carcinoma.
Sugg SL; Ezzat S; Zheng L; Freeman JL; Rosen IB; Asa SL
Surgery; 1999 Jan; 125(1):46-52. PubMed ID: 9889797
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness.
LeRiche VK; Asa SL; Ezzat S
J Clin Endocrinol Metab; 1996 Feb; 81(2):656-62. PubMed ID: 8636285
[TBL] [Abstract][Full Text] [Related]
16. The GnRH receptor gene is preferentially expressed in functioning gonadotroph adenomas and displays a Mae III polymorphism site.
Kottler ML; Seret-Bégué D; Lahlou N; Assayag M; Carré MC; Lagarde JP; Ajzenberg C; Christin-Maitre S; Bouchard P; Mikol J; Counis R; Warnet A
Clin Endocrinol (Oxf); 1998 Jul; 49(1):115-23. PubMed ID: 9797855
[TBL] [Abstract][Full Text] [Related]
17. Expression of prolactin-releasing peptide and its receptor messenger ribonucleic acid in normal human pituitary and pituitary adenomas.
Zhang X; Danila DC; Katai M; Swearingen B; Klibanski A
J Clin Endocrinol Metab; 1999 Dec; 84(12):4652-5. PubMed ID: 10599733
[TBL] [Abstract][Full Text] [Related]
18. Expression and amplification of neu oncogene in pleomorphic adenomas of salivary gland.
Kahn HJ; Hanna W; Auger M; Andrulis I
Arch Pathol Lab Med; 1992 Jan; 116(1):80-3. PubMed ID: 1346490
[TBL] [Abstract][Full Text] [Related]
19. The MEN-1 gene is rarely down-regulated in pituitary adenomas.
Asa SL; Somers K; Ezzat S
J Clin Endocrinol Metab; 1998 Sep; 83(9):3210-2. PubMed ID: 9745428
[TBL] [Abstract][Full Text] [Related]
20. Expression of neuro D1 in human normal pituitaries and pituitary adenomas.
Oyama K; Sanno N; Teramoto A; Osamura RY
Mod Pathol; 2001 Sep; 14(9):892-9. PubMed ID: 11557786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
